Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 15/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21367487 | 0.84 | CD274 (0.58) | CD274 | |
| SCHEMBL10351965 | 0.79 | ALDH1A1 (0.46) | CD274KDM4EL3MBTL1ALDH1A1GAA | |
| SCHEMBL20147802 | 0.78 | ADORA1 (0.52) | ADORA2AADORA1KDM4EALDH1A1HPGD | |
| SCHEMBL18406701 | 0.76 | ADORA2A (0.51) | ADORA2AADORA1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL20356610 | 0.76 | CD274 (0.64) | CD274KDM4EALDH1A1GAA | |
| SCHEMBL13074967 | 0.76 | KDM4E (0.48) | KDM4EL3MBTL1ALDH1A1GAAHPGD | |
| SCHEMBL15456146 | 0.73 | ADRA2C (0.45) | CD274ADORA2AADORA1FFAR1FFAR4 | |
| SCHEMBL15680092 | 0.73 | KDM4E (0.45) | CD274KDM4EL3MBTL1ALDH1A1GAA | |
| SCHEMBL30825314 | 0.72 | ALDH1A1 (0.54) | ADORA2AADORA1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL20237969 | 0.71 | HTR2A (0.44) | CD274KDM4EL3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | CD274 4563/4885ADORA2A 2795/4885ADORA1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.